Tougher FDA enforcement in the works

Share this article:
House Energy and Commerce Committee chairman John Dingell (D-MI) is circulating a revised draft of his proposed FDA Globalization Act, incorporating changes negotiated by committee staffers with the FDA and the drug industry since the original draft was released in April. Committee spokeswoman Brin Frazier said in the first week of August that changes, including hefty new monetary and imprisonment penalties for violations, were still being worked on and none had been finalized. 

The revision applies only to the drug safety section and would lengthen the time for risk-based inspections of manufacturing facilities to once every four years. FDA officials reportedly told the committee they needed such flexibility to allocate limited resources based on risk. The revision would require the FDA to establish a system for assessing risk and determining inspection intervals within three years of the bill's passage.

The amount to be charged in registration fees to cover the costs of new safety activities has not been determined. There are strengthened drug pedigree requirements and subpoena powers for the FDA, and a condition for labeling to show the active ingredients' country of origin.

Co-sponsored with Reps. Frank Pallone (D-NJ) and Bart Stupak (D-MI), the proposed bill is widely regarded as being the possible genesis of the most sweeping FDA overhaul in a generation. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?